letrozole has been researched along with Hot Flashes in 10 studies
Hot Flashes: A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "Letrozole-treated patients with rs2077647 (T>C) variants CC and TC had a reduced risk of bone AE (HR = 0." | 6.80 | ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. ( Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B, 2015) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "Letrozole was superior to exemestane in relieving the endometriosis-associated pain in this postmenopausal woman." | 3.74 | Aromatase inhibitors in the treatment of severe endometriosis. ( Bedaiwy, MA; Casper, RF; Mousa, NA, 2007) |
| "Letrozole-treated patients with rs2077647 (T>C) variants CC and TC had a reduced risk of bone AE (HR = 0." | 2.80 | ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. ( Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B, 2015) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Uterine fibroids, also called uterine leiomyomas or myomas, are the most common benign tumours in women of reproductive age." | 2.49 | Aromatase inhibitors for uterine fibroids. ( Lu, D; Navaratnam, K; Shi, G; Song, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kyvernitakis, I | 1 |
| Ziller, V | 1 |
| Hars, O | 1 |
| Bauer, M | 1 |
| Kalder, M | 1 |
| Hadji, P | 1 |
| Song, H | 1 |
| Lu, D | 1 |
| Navaratnam, K | 1 |
| Shi, G | 1 |
| Leyland-Jones, B | 1 |
| Gray, KP | 1 |
| Abramovitz, M | 1 |
| Bouzyk, M | 1 |
| Young, B | 1 |
| Long, B | 1 |
| Kammler, R | 1 |
| Dell'Orto, P | 1 |
| Biasi, MO | 1 |
| Thürlimann, B | 1 |
| Harvey, V | 1 |
| Neven, P | 2 |
| Arnould, L | 1 |
| Maibach, R | 1 |
| Price, KN | 1 |
| Coates, AS | 1 |
| Goldhirsch, A | 1 |
| Gelber, RD | 1 |
| Pagani, O | 1 |
| Viale, G | 1 |
| Rae, JM | 1 |
| Regan, MM | 1 |
| Smith, I | 1 |
| Yardley, D | 1 |
| Burris, H | 1 |
| De Boer, R | 1 |
| Amadori, D | 1 |
| McIntyre, K | 1 |
| Ejlertsen, B | 1 |
| Gnant, M | 1 |
| Jonat, W | 1 |
| Pritchard, KI | 1 |
| Dowsett, M | 1 |
| Hart, L | 1 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| O'Shaughnessy, J | 1 |
| Parsanezhad, ME | 1 |
| Azmoon, M | 1 |
| Alborzi, S | 1 |
| Rajaeefard, A | 1 |
| Zarei, A | 1 |
| Kazerooni, T | 1 |
| Frank, V | 1 |
| Schmidt, EH | 1 |
| Morales, L | 1 |
| Timmerman, D | 1 |
| Christiaens, MR | 1 |
| Vergote, I | 1 |
| Van Limbergen, E | 1 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Paridaens, R | 1 |
| Mousa, NA | 1 |
| Bedaiwy, MA | 1 |
| Casper, RF | 1 |
| Perez, EA | 1 |
| Thomas, R | 1 |
| Williams, M | 1 |
| Marshall, C | 1 |
| Walker, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Light Emitting Diode for the Treatment of Genitourinary Syndrome of Menopause Associated With Hormonal Therapy for Treating Breast Cancer: Randomized Controlled Clinical Trial[NCT03833726] | 77 participants (Actual) | Interventional | 2019-01-30 | Completed | |||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns[NCT01280045] | 5 participants (Actual) | Interventional | 2011-01-31 | Terminated (stopped due to No grant was received then we stopped the recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for letrozole and Hot Flashes
| Article | Year |
|---|---|
Aromatase inhibitors for uterine fibroids.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Female; Hot Flashes; Humans; Leiomyoma; Letrozole; Nitr | 2013 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
6 trials available for letrozole and Hot Flashes
| Article | Year |
|---|---|
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; | 2014 |
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Early Detectio | 2015 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Topics: Adult; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Estradiol; Female; Follicle Stimulatin | 2010 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Ne | 2008 |
2 other studies available for letrozole and Hot Flashes
| Article | Year |
|---|---|
Aromatase inhibitors in the treatment of severe endometriosis.
Topics: Androstadienes; Aromatase Inhibitors; Chronic Disease; Endometriosis; Estrogen Replacement Therapy; | 2007 |
Toremifene and letrozole for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clin | 1998 |